In in vitro studies using prostate cancer cell lines, rosiglitazone might inhibit the migration and invasion of prostate cancer cells through its inhibitory effect on the CXCR4/CXCL12 axis (28) and downregulation of vascular endothelial growth factor (29). The gene discussed is CXCR4; the disease is prostate cancer.